Ovarian cancer
Not recruitingStudy of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment
Study of tuvusertib combined with niraparib or lartesertib for patients with ovarian cancer that worsened after previous PARP inhibitor treatment
- Disease:Ovarian cancer
- Substances:Tuvusertib2-Amino-6-Fluoro-N-(5-Fluoro-4-(1-Methyl-1H-Imidazol-5-Yl)Pyridin-3-Yl)Pyrazolo[1,5-A]Pyrimidine-3-Carboxamide+2
France- Participants:18–64 years · 65+ years
- Substances:Tuvusertib
- Sponsor:Merck Healthcare KGaA












